Metastatic Renal Cell Carcinoma: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management - Episode 12

Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens

, ,

David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.